Lumos Pharma Stock Price on December 16, 2024

LUMO Stock  USD 4.34  0.01  0.23%   
Below is the normalized historical share price chart for Lumos Pharma extending back to November 14, 2011. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Lumos Pharma stands at 4.34, as last reported on the 17th of December 2024, with the highest price reaching 4.39 and the lowest price hitting 4.33 during the day.
IPO Date
11th of November 2011
200 Day MA
3.0906
50 Day MA
4.2024
Beta
0.331
 
Yuan Drop
 
Covid
If you're considering investing in Lumos Stock, it is important to understand the factors that can impact its price. Lumos Pharma appears to be somewhat reliable, given 3 months investment horizon. Lumos Pharma has Sharpe Ratio of 0.0983, which conveys that the firm had a 0.0983% return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Lumos Pharma, which you can use to evaluate the volatility of the firm. Please exercise Lumos Pharma's Risk Adjusted Performance of 0.0876, mean deviation of 2.14, and Downside Deviation of 3.02 to check out if our risk estimates are consistent with your expectations.
  
At this time, Lumos Pharma's Other Stockholder Equity is very stable compared to the past year. As of the 17th of December 2024, Capital Stock is likely to grow to about 143.5 K, while Total Stockholder Equity is likely to drop about 25.9 M. . At this time, Lumos Pharma's Price Book Value Ratio is very stable compared to the past year. As of the 17th of December 2024, Price To Book Ratio is likely to grow to 1.00, while Price To Sales Ratio is likely to drop 12.00. Lumos Stock price history is provided at the adjusted basis, taking into account all of the recent filings.

Sharpe Ratio = 0.0983

Best PortfolioBest Equity
Good Returns
Average Returns
Small ReturnsLUMO
CashSmall RiskAverage RiskHigh RiskHuge Risk
Negative Returns

Estimated Market Risk

 3.16
  actual daily
28
72% of assets are more volatile

Expected Return

 0.31
  actual daily
6
94% of assets have higher returns

Risk-Adjusted Return

 0.1
  actual daily
7
93% of assets perform better
Based on monthly moving average Lumos Pharma is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lumos Pharma by adding it to a well-diversified portfolio.
Price Book
7.6384
Enterprise Value Ebitda
0.3853
Price Sales
17.0227
Shares Float
5.7 M
Wall Street Target Price
4.25

Related Headline

Rezolute Headline on 16th of December 2024

Filed transaction by Rezolute Officer Cfo. Grant, award or other acquisition pursuant to Rule 16b-3

Lumos Pharma Valuation on December 16, 2024

It is possible to determine the worth of Lumos Pharma on a given historical date. On December 16, 2024 Lumos was worth 4.33 at the beginning of the trading date compared to the closed value of 4.34. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Lumos Pharma stock. Still, in general, we apply an absolute valuation method to find Lumos Pharma's value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Lumos Pharma where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Lumos Pharma's related companies.
 Open High Low Close Volume
  4.33    4.39    4.33    4.34    481,687  
12/17/2024
  4.33    4.39    4.33    4.34    0.00  
Backtest Lumos Pharma  |  Lumos Pharma History  |  Lumos Pharma Valuation   Previous
Open Value
4.33
4.34
Closing Value
13.80
Upside

Lumos Pharma Trading Date Momentum on December 16, 2024

On December 17 2024 Lumos Pharma was traded for  4.34  at the closing time. The top price for the day was 4.39  and the lowest listed price was  4.33 . There was no trading activity during the period 0.0. Lack of trading volume on December 17, 2024 did not cause price change. The trading delta at closing time against the current closing price is 0.23% .

Lumos Pharma Fundamentals Correlations and Trends

By evaluating Lumos Pharma's financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Lumos Pharma's main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Lumos financial account trend analysis is a perfect complement when working with valuation or volatility modules.

About Lumos Pharma Stock history

Lumos Pharma investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Lumos is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Lumos Pharma will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Lumos Pharma stock prices may prove useful in developing a viable investing in Lumos Pharma
Last ReportedProjected for Next Year
Common Stock Shares Outstanding8.1 M4.1 M
Net Loss-35.7 M-37.5 M

Lumos Pharma Quarterly Net Working Capital

10.77 Million

Lumos Pharma Stock Technical Analysis

Lumos Pharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Lumos Pharma technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Lumos Pharma trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

Price Boundaries

Lumos Pharma Period Price Range

Low
December 17, 2024
0.00  NaN%
High

 0.00 

     

 0.00 

Lumos Pharma cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.

Lumos Pharma December 17, 2024 Market Strength

Market strength indicators help investors to evaluate how Lumos Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Lumos Pharma shares will generate the highest return on investment. By undertsting and applying Lumos Pharma stock market strength indicators, traders can identify Lumos Pharma entry and exit signals to maximize returns

Lumos Pharma Technical and Predictive Indicators

Predictive indicators are helping investors to find signals for Lumos Pharma's price direction in advance. Along with the technical and fundamental analysis of Lumos Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Lumos to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
When determining whether Lumos Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lumos Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lumos Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lumos Pharma Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lumos Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.
You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lumos Pharma. If investors know Lumos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lumos Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.28)
Revenue Per Share
0.27
Quarterly Revenue Growth
102.714
Return On Assets
(0.70)
Return On Equity
(1.73)
The market value of Lumos Pharma is measured differently than its book value, which is the value of Lumos that is recorded on the company's balance sheet. Investors also form their own opinion of Lumos Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lumos Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lumos Pharma's market value can be influenced by many factors that don't directly affect Lumos Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lumos Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lumos Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lumos Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.